DXCM vs RAPP · P/E 63, rev $2.50B vs rev $20.0M
DexCom Inc (DXCM) versus Rapport Therapeutics, Inc. Common Stock (RAPP) — a side-by-side from cached financials, not a winner call.
DexCom Inc (DXCM) is a medical devices company listed on US.
Rapport Therapeutics, Inc. Common Stock (RAPP) is a biotechnology company listed on US.
Latest reported DXCM revenue for 2026-06-30 was $2.50B. Net income was $448.6M. DXCM currently screens at market cap $32.84B and trailing P/E 62.5.
Latest reported RAPP revenue for 2026-06-30 was $20.0M. Net income was -$76.5M. Revenue was up 0.0% from 2026-03-31 to 2026-06-30. RAPP currently screens at market cap $532.9M.
DXCM currently screens at market cap $32.84B and trailing P/E 62.5. RAPP currently screens at market cap $532.9M.
Not investment advice. Open the DXCM and RAPP stock pages for the full models.
Not investment advice.